Literature DB >> 8698054

Diastolic or systolic left and right ventricular impairment at moderate doses of anthracycline? A 1-year follow-up study of women.

Y Cottin1, C Touzery, B Coudert, S Richebourg, M Cohen, M Toubeau, P Louis, J E Wolf, F Brunotte.   

Abstract

A prospective study was carried out to assess the early and later alterations in left and right ventricular diastolic and systolic function after the termination of anthracycline therapy. In 33 women without cardiac disease who were treated by anthracycline therapy, cardiac function was evaluated by radionuclide angiography before the treatment (T0) and 1 month (T1) and 12 months (T12) after the end of the treatment. Cardiac function was assessed by radionuclide measurement throughout treatment. Analysis of ejection fraction (EF), peak ejection rate (PER), time to PER (TPER), peak filling rate (PFR) and time to PFR (TPFR) was performed before and after treatment. To normalise radionuclide measurements of the ventricular diastolic function, the ratio of the PFR and the EF and the ratio of the PFR and the PER were calculated. No patient developed symptomatic congestive cardiac failure. One-way analysis of variance showed a significant decrease in the three parameters (EF, PER, PFR) over time only for the left ventricle (LV); no significant alterations appeared for the right ventricle (RV). The EF of the LV decreased from 59%+/-5% at T0 to 57%+/-6% at T1 and 56%+/-5% at T12. The PER of the LV fell from 3.03+/-0.40 end-diastolic volume per second (EDV/s) at T0 to 2.79+/-0.47 at T1 and 2.78+/-0.43 at T12. The PFR of the LV dropped from 2.99+/-0.43 EDV/s at T0 to 2.62+/-0.44 at T1 and 2.56+/-0.42 at T12. For the normalised ratios, no differences were observed. Significant differences were found for EF, PER and PFR between T0 and T1, and between T0 and T12, but no difference was found between T1 and T12. This report shows simultaneous impairment of the systolic and diastolic LV radionuclide parameters at 1 and 12 months after anthracycline therapy without alteration in the RV function.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8698054     DOI: 10.1007/bf00833384

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  34 in total

1.  Alterations of intracellular calcium homeostasis and myocardial energetics in acute adriamycin-induced heart failure.

Authors:  H Kusuoka; S Futaki; Y Koretsune; A Kitabatake; H Suga; T Kamada; M Inoue
Journal:  J Cardiovasc Pharmacol       Date:  1991-09       Impact factor: 3.105

2.  A general mechanism for microsomal activation of quinone anticancer agents to free radicals.

Authors:  N R Bachur; S L Gordon; M V Gee
Journal:  Cancer Res       Date:  1978-06       Impact factor: 12.701

3.  Increased risk of cardiac dysfunction after anthracyclines in girls.

Authors:  J H Silber; R I Jakacki; R L Larsen; J W Goldwein; G Barber
Journal:  Med Pediatr Oncol       Date:  1993

4.  Normalised radionuclide measures of left ventricular diastolic function.

Authors:  K J Lee; A E Southee; G J Bautovich; B Freedman; A F McLaughlin; M A Rossleigh; B F Hutton; J G Morris
Journal:  Eur J Nucl Med       Date:  1989

5.  Right ventricular overload and induced sustained ventricular tachycardia in operatively "repaired" tetralogy of Fallot.

Authors:  P Y Marie; F Marçon; F Brunotte; S Briançon; N Danchin; A M Worms; J Robert; C Pernot
Journal:  Am J Cardiol       Date:  1992-03-15       Impact factor: 2.778

6.  Cardiac toxicity 4 to 20 years after completing anthracycline therapy.

Authors:  L J Steinherz; P G Steinherz; C T Tan; G Heller; M L Murphy
Journal:  JAMA       Date:  1991-09-25       Impact factor: 56.272

7.  Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity.

Authors:  J H McKillop; M R Bristow; M L Goris; M E Billingham; K Bockemuehl
Journal:  Am Heart J       Date:  1983-11       Impact factor: 4.749

8.  Acute adriamycin cardiotoxicity in rats.

Authors:  E A Porta; N S Joun; L Matsumura; B Nakasone; H Sablan
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1983-07

9.  Comparative microscopic study of cardiotoxicity and skin toxicity of anthracycline analogs.

Authors:  D Dantchev; G Balercia; C Bourut; A Anjo; R Maral; G Mathé
Journal:  Biomed Pharmacother       Date:  1984       Impact factor: 6.529

10.  Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography.

Authors:  R G Schwartz; W B McKenzie; J Alexander; P Sager; A D'Souza; A Manatunga; P E Schwartz; H J Berger; J Setaro; L Surkin
Journal:  Am J Med       Date:  1987-06       Impact factor: 4.965

View more
  8 in total

Review 1.  Cardiotoxicity due to chemotherapy: role of cardiac imaging.

Authors:  Frédéric Poulin; Paaladinesh Thavendiranathan
Journal:  Curr Cardiol Rep       Date:  2015-03       Impact factor: 2.931

2.  Echocardiography for Evaluation of Oncology Therapy-Related Cardiotoxicity.

Authors:  Chun-Li Wang; Pao-Hsien Chu
Journal:  Acta Cardiol Sin       Date:  2016-09       Impact factor: 2.672

Review 3.  The influence of chemotherapy on the right ventricle: did we forget something?

Authors:  Marijana Tadic; Cesare Cuspidi; Dagmara Hering; Lucia Venneri; Oleksandr Danylenko
Journal:  Clin Cardiol       Date:  2017-02-13       Impact factor: 2.882

4.  Cardiac functional evaluation using vector velocity imaging after chemotherapy including anthracyclines in children with cancer.

Authors:  Jong Hun Park; Yeo Hyang Kim; Myung Chul Hyun; Heung Sik Kim
Journal:  Korean Circ J       Date:  2009-09-30       Impact factor: 3.243

5.  Longitudinal assessment of right ventricular structure and function by cardiovascular magnetic resonance in breast cancer patients treated with trastuzumab: a prospective observational study.

Authors:  Ashita Barthur; Christine Brezden-Masley; Kim A Connelly; Vinita Dhir; Kelvin K W Chan; Rashida Haq; Anish Kirpalani; Joseph J Barfett; Laura Jimenez-Juan; Gauri R Karur; Djeven P Deva; Andrew T Yan
Journal:  J Cardiovasc Magn Reson       Date:  2017-04-10       Impact factor: 5.364

6.  Right Ventricular Dysfunction in Patients Experiencing Cardiotoxicity during Breast Cancer Therapy.

Authors:  Anna Calleja; Frédéric Poulin; Ciril Khorolsky; Masoud Shariat; Philippe L Bedard; Eitan Amir; Harry Rakowski; Michael McDonald; Diego Delgado; Paaladinesh Thavendiranathan
Journal:  J Oncol       Date:  2015-08-03       Impact factor: 4.375

7.  Right heart function deteriorates in breast cancer patients undergoing anthracycline-based chemotherapy.

Authors:  Kevin Emery Boczar; Olexiy Aseyev; Jeffrey Sulpher; Christopher Johnson; Ian G Burwash; Michele Turek; Susan Dent; Girish Dwivedi
Journal:  Echo Res Pract       Date:  2016-07-25

8.  Right ventricular 2D speckle-tracking echocardiography in children with osteosarcoma under chemotherapy.

Authors:  Ibtsam Khairat; Mohamed Khalfallah; Aliaa Shaban; Ibrahim Abu Farag; Asmaa Elkady
Journal:  Egypt Heart J       Date:  2019-11-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.